

# Blanca E Ocampo-García

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5187244/publications.pdf>

Version: 2024-02-01

72  
papers

1,538  
citations

257450

24  
h-index

345221

36  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis and Preclinical Assessment of $^{99m}\text{Tc}$ -iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. <i>Molecules</i> , 2022, 27, 264.	3.8	16
2	Targeted Endoradiotherapy with $\text{Lu}_2\text{O}_3$ -iPSMA/iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image. <i>Pharmaceutics</i> , 2022, 14, 720.	4.5	8
3	$^{225}\text{Ac}$ -rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins. <i>Molecules</i> , 2022, 27, 2156.	3.8	5
4	$^{[99m]\text{Tc}}\text{Tc}$ -iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients. <i>Pharmaceutics</i> , 2022, 15, 590.	3.8	3
5	IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 1060.	4.5	2
6	Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer. <i>Pharmaceutics</i> , 2022, 14, 1095.	4.5	7
7	$^{[99m]\text{Tc}}\text{Tc}$ -iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities. <i>Pharmaceutics</i> , 2022, 15, 729.	3.8	7
8	Drug Delivery Systemsâ€Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2000362.	4.1	11
9	Development of $^{177}\text{Lu}$ -DN(C19)-CXCR4 Ligand Nanosystem for Combinatorial Therapy in Pancreatic Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 263-278.	1.1	11
10	Electron transfer reactions in rhodamine: Potential use in photodynamic therapy. <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2021, 409, 113131.	3.9	8
11	$^{[68\text{Ga}]\text{Ga}}$ -iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 54-60.	0.6	10
12	Preclinical dosimetric studies of $^{177}\text{Lu}$ - $^{177}\text{Lu}$ - $^{177}\text{Lu}$ -FvD2B and comparison with $^{177}\text{Lu}$ -iPSMAâ€17 and $^{177}\text{Lu}$ -iPSMA endoradiotherapeutic agents. <i>Medical Physics</i> , 2021, 48, 4064-4074.	3.0	3
13	Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. <i>Pharmaceutics</i> , 2021, 13, 1123.	4.5	10
14	Preparation and Dosimetry Assessment of $^{166}\text{Dy}$ - $^{166}\text{Ho}$ - $^{166}\text{Ho}$ -iPSMA Nanoparticles for Targeted Hepatocarcinoma Radiotherapy. <i>Journal of Nanoscience and Nanotechnology</i> , 2021, 21, 5449-5458.	0.9	2
15	Targeted photodynamic therapy using reconstituted high-density lipoproteins as rhodamine transporters. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 37, 102630.	2.6	2
16	Synthesis, chemical and biochemical characterization of $\text{Lu}_2\text{O}_3$ -iPSMA nanoparticles activated by neutron irradiation. <i>Materials Science and Engineering C</i> , 2020, 117, 111335.	7.3	12
17	$^{99m}\text{Tc}$ -CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans. <i>Contrast Media and Molecular Imaging</i> , 2020, 2020, 1-10.	0.8	8
18	Hybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer. <i>Contrast Media and Molecular Imaging</i> , 2020, 2020, 1-7.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Development of <sup>177</sup> Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. <i>Scientific Reports</i> , 2020, 10, 9313.	3.3	11
20	Synthesis and preclinical evaluation of the <sup>99m</sup> Tc-/ <sup>177</sup> Lu-CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 324, 21-32.	1.5	16
21	Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide. <i>Journal of Biomedical Nanotechnology</i> , 2020, 16, 689-701.	1.1	10
22	Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 7032-7047.	2.4	5
23	<sup>177</sup> Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. <i>Materials Science and Engineering C</i> , 2019, 105, 110043.	7.3	42
24	Synthesis and Evaluation of <sup>177</sup> Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug Therapeutic Effect on Breast Cancer Cells. <i>Polymers</i> , 2019, 11, 1572.	4.5	27
25	[ <sup>99m</sup> Tc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging. <i>Nanoscale</i> , 2019, 11, 541-551.	5.6	18
26	Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. <i>Materials Science and Engineering C</i> , 2019, 103, 109766.	7.3	63
27	Synthesis and preclinical evaluation of the <sup>177</sup> Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer. <i>Nuclear Medicine Communications</i> , 2019, 40, 278-286.	1.1	19
28	Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. <i>Ecoproduction</i> , 2019, , 201-219.	0.8	0
29	<sup>177</sup> Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-10.	0.8	15
30	<sup>177</sup> Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 318, 2059-2066.	1.5	13
31	In vitro and in vivo synergistic effect of radiotherapy and plasmonic photothermal therapy on the viability of cancer cells using <sup>177</sup> Lu- <sup>64</sup> Au-NLS-RGD-Aptamer nanoparticles under laser irradiation. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 318, 1913-1921.	1.5	14
32	Preparation and preclinical evaluation of <sup>68</sup> Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 318, 2097-2105.	1.5	19
33	Clinical translation of a PSMA inhibitor for <sup>99m</sup> Tc-based SPECT. <i>Nuclear Medicine and Biology</i> , 2017, 48, 36-44.	0.6	52
34	<sup>99m</sup> Tc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients. <i>Nuclear Medicine and Biology</i> , 2017, 52, 1-6.	0.6	28
35	Biodegradable poly(D,L-lactide-co-glycolide)/poly(L- <sup>13</sup> C-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin. <i>Materials Science and Engineering C</i> , 2017, 76, 743-751.	7.3	43
36	Physicochemical behaviour of a dinuclear uranyl complex formed with an octaphosphinoylated para-tert-butylcalix[8]arene. Spectroscopic studies in solution and in the solid state. <i>Polyhedron</i> , 2017, 123, 75-89.	2.2	4

#	ARTICLE	IF	CITATIONS
37	99mTc-exendin(9-39)/octreotide. Nuclear Medicine Communications, 2017, 38, 912-918.	1.1	4
38	Synthesis and in vitro evaluation of an antiangiogenic cancer-specific dual-targeting <sup>177</sup> Lu-Au-nanoradiopharmaceutical. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 1337-1345.	1.5	8
39	Preparation and in vitro evaluation of <sup>177</sup> Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 2201-2207.	1.5	10
40	Preclinical Biokinetic Modelling of Tc-99m Radiopharmaceuticals Obtained from Semi-Automatic Image Processing. Journal of Medical and Biological Engineering, 2017, 37, 887-898.	1.8	2
41	Fluorescent, Plasmonic, and Radiotherapeutic Properties of the <sup>177</sup> Lu-Dendrimer-AuNP-Folate-Bombesin Nanoprobe Located Inside Cancer Cells. Molecular Imaging, 2017, 16, 153601211770476.	1.4	39
42	Preparation and Characterization of a Tumor-Targeting Dual-Image System Based on Iron Oxide Nanoparticles Functionalized with Folic Acid and Rhodamine. Journal of Nanomaterials, 2017, 2017, 1-11.	2.7	6
43	Antibacterial Efficacy of Gold and Silver Nanoparticles Functionalized with the Ubiquicidin (29-41) Antimicrobial Peptide. Journal of Nanomaterials, 2017, 2017, 1-10.	2.7	37
44	Multimeric System of RGD-Grafted PMMA-Nanoparticles as a Targeted Drug-Delivery System for Paclitaxel. Current Pharmaceutical Design, 2017, 23, 3415-3422.	1.9	8
45	<sup>177</sup> Lu-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical. Journal of Nanomaterials, 2016, 2016, 1-11.	2.7	40
46	Improved radiopharmaceutical based on 99mTc-Bombesin-folate for breast tumour imaging. Nuclear Medicine Communications, 2016, 37, 377-386.	1.1	14
47	Hydrogels based on poly(ethylene glycol) as scaffolds for tissue engineering application: biocompatibility assessment and effect of the sterilization process. Journal of Materials Science: Materials in Medicine, 2016, 27, 176.	3.6	44
48	Synthesis and evaluation of Lys 1 (± <sup>125</sup> I-Folate)Lys 3 ( <sup>177</sup> Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer. Applied Radiation and Isotopes, 2016, 107, 214-219.	1.5	26
49	Comparative Effect Between Laser and Radiofrequency Heating of RGD-Gold Nanospheres on MCF7 Cell Viability. Journal of Nanoscience and Nanotechnology, 2015, 15, 9840-9848.	0.9	5
50	Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging. Journal of Nanoscience and Nanotechnology, 2015, 15, 4159-4169.	0.9	24
51	A freeze-dried kit formulation for the preparation of Lys 27 ( <sup>99m</sup> Tc-EDDA/HYNIC)-Exendin(9-39)/ <sup>99m</sup> Tc-EDDA/HYNIC-Tyr 3 -Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology, 2015, 42, 911-916.	0.6	6
52	Preparation of Heterobivalent and Multivalent Radiopharmaceuticals to Target Tumors Over-Expressing Integrins. Methods in Pharmacology and Toxicology, 2015, , 69-92.	0.2	0
53	Tumoral fibrosis effect on the radiation absorbed dose of <sup>177</sup> Lu-Tyr3-octreotate and <sup>177</sup> Lu-Tyr3-octreotate conjugated to gold nanoparticles. Applied Radiation and Isotopes, 2015, 100, 96-100.	1.5	6
54	Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup> Lu and Conjugated to Peptides. Current Radiopharmaceuticals, 2015, 8, 150-159.	0.8	28

#	ARTICLE	IF	CITATIONS
55	Kit preparation and biokinetics in women of <sup>99m</sup> Tc-EDDA/HYNIC-E-[c(RGDfK)] <sub>2</sub> for breast cancer imaging. Nuclear Medicine Communications, 2014, 35, 423-432.	1.1	23
56	Molecular Targeting Radiotherapy with Cyclo-RGDfK(C) Peptides Conjugated to <sup>177</sup> Lu-Labeled Gold Nanoparticles in Tumor-Bearing Mice. Journal of Biomedical Nanotechnology, 2014, 10, 393-404.	1.1	95
57	Design and biological evaluation of <sup>99m</sup> Tc-N2S2-Tat(49 <sup>57</sup> )-c(RGDyK): A hybrid radiopharmaceutical for tumors expressing $\alpha_5\beta_3$ integrins. Nuclear Medicine and Biology, 2013, 40, 481-487.	0.6	13
58	Laser Heating of Gold Nanospheres Functionalized with Octreotide: <i>In Vitro</i> Effect on HeLa Cell Viability. Photomedicine and Laser Surgery, 2013, 31, 17-22.	2.0	28
59	Multifunctional targeted therapy system based on <sup>99m</sup> Tc/ <sup>177</sup> Lu-labeled gold nanoparticles-Tat(49 <sup>57</sup> )-Lys <sub>3</sub> -bombesin internalized in nuclei of prostate cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 663-671.	1.0	73
60	Multifunctional Radiolabeled Nanoparticles for Targeted Therapy. Current Medicinal Chemistry, 2013, 21, 124-138.	2.4	41
61	Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms. Current Pharmaceutical Design, 2012, 18, 1098-1106.	1.9	25
62	Multifunctional Targeted Radiotherapy System for Induced Tumours Expressing Gastrin-releasing Peptide Receptors. Current Nanoscience, 2012, 8, 193-201.	1.2	14
63	Engineered Multifunctional RGD-Gold Nanoparticles for the Detection of Tumour-Specific $\alpha_5\beta_3$ Expression: Chemical Characterisation and Ecotoxicological Risk Assessment. Journal of Biomedical Nanotechnology, 2012, 8, 991-999.	1.1	14
64	Cyclization of RGD peptide sequences via the macrocyclic chelator DOTA for integrin imaging. Dalton Transactions, 2012, 41, 14051.	3.3	9
65	<sup>177</sup> Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing $\alpha_5\beta_3$ integrins. Journal of Labelled Compounds and Radiopharmaceuticals, 2012, 55, 140-148.	1.0	31
66	Multimeric System of <sup>99m</sup> Tc-Labeled Gold Nanoparticles Conjugated to c[RGDfK(C)] for Molecular Imaging of Tumor $\alpha_5\beta_3$ Expression. Bioconjugate Chemistry, 2011, 22, 913-922.	3.6	114
67	<sup>99m</sup> Tc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nuclear Medicine and Biology, 2011, 38, 1-11.	0.6	79
68	Kit for preparation of multimeric receptor-specific <sup>99m</sup> Tc-radiopharmaceuticals based on gold nanoparticles. Nuclear Medicine Communications, 2011, 32, 1095-1104.	1.1	29
69	Lys <sub>3</sub> -Bombesin Conjugated to <sup>99m</sup> Tc-Labeled Gold Nanoparticles for <i>In Vivo</i> Gastrin Releasing Peptide-Receptor Imaging. Journal of Biomedical Nanotechnology, 2010, 6, 375-384.	1.1	47
70	Click chemistry for [ <sup>99m</sup> Tc(CO) <sub>3</sub> ] labeling of Lys <sub>3</sub> -bombesin. Applied Radiation and Isotopes, 2010, 68, 2274-2278.	1.5	13
71	Biokinetics of [ <sup>99m</sup> Tc]-labeled gold nanoparticles conjugated to mannose for specific sentinel node detection. , 2010, , .		0
72	Gold nanoparticles conjugated to [Tyr <sup>3</sup> ]Octreotide peptide. Biophysical Chemistry, 2008, 138, 83-90.	2.8	50